Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation

Oncogene volume 21, pages 2141–2153 (2002)Cite this article

Abstract

Although ganciclovir (GCV) is most often used in suicide anticancer gene therapy, the mechanism of GCV-induced cell killing and apoptosis is not fully understood. We analysed the mechanism of apoptosis triggered by GCV using a model system of CHO cells stably transfected with HSV-1 thymidine kinase (HSVtk). GCV-induced apoptosis is due to incorporation of the drug into DNA resulting in replication-dependent formation of DNA double-strand breaks and, at later stages, S and G2/M arrest. GCV-provoked DNA instability was likely to be responsible for the observed initial decline in Bcl-2 level and caspase-9/-3 activation. Further decline in the Bcl-2 level was due to cleavage of the protein by caspase-9, as demonstrated by use of caspase inhibitors and transfection with trans-dominant negative caspase expression vectors. Bcl-2 cleavage resulted in the appearance of a pro-apoptotic 23 kDa Bcl-2 fragment and in excessive cytochrome c release, dephosphorylation of BAD, cleavage of PARP and finally DNA degradation. Since Fas/CD95 and caspase-8 were only slightly activated we conclude GCV-induced apoptosis to occur in this cell system mainly by activating the mitochondrial damage pathway. This process is independent of p53 for which the cells are mutated. Caspase-9 mediated cleavage of Bcl-2 accelerates the apoptotic process and may explain the high potential of GCV to induce apoptosis. Data are also discussed as to implications for HSVtk gene therapy utilizing GCV.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Beltinger C, Fulda S, Kammertoens T, Meyer E, Uckert W, Debatin K-M . 1999 Proc. Natl. Acad. Sci. USA 96: 8699–8704

  • Beltinger C, Fulda S, Kammertoens T, Uckert W, Debatin K-M . 2000 Cancer Res. 60: 3212–3217

  • Bossy-Wetzel E, Newmeyer DD, Green DR . 1998 EMBO J. 17: 37–49

  • Bradford MM . 1976 Anal. Biochem. 72: 248–254

  • Cheng E H-Y, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM . 1997 Science 278: 1966–1968

  • Craperi D, Virat JM, Nisson MF, Mathieu J, Baudier J, Benabid AL, Verna JM . 1999 Hum. Gene Ther. 10: 679–688

  • Crumpacker CS . 1996 N. Engl. J. Med. 335: 721–729

  • Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME . 1997 Cell 91: 231–241

  • Duan H, Orth K, Chinnaiyan AM, Poirier GG, Froelich CJ, HE W-W, Dixit VM . 1996 J. Biol. Chem. 271: 16720–16724

  • Dunkern TR, Fritz G, Kaina B . 2001 Oncogene 20: 6026–6038

  • Feinmesser M, Halpern M, Fenig E, Tsabari C, Hodak E, Sulkes J, Brenner B, Okon E . 1999 Human Path. 30: 1367–1372

  • Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM, Giaconne G . 2000 Clin. Cancer Res. 6: 203–212

  • Fujita N, Tsuruo T . 1998 Biochem. Biophys. Res. Commun. 246: 484–488

  • Gallo O, Chiarelli I, Boddi V, Bocciolini C, Bruschini L, Porfiri B . 1999 Int. J. Cancer 84: 573–579

  • Grangirard D, Studer E, Monney L, Belser T, Fellay I, Borner C, Michel MR . 1998 EMBO J. 17: 1268–1278

  • Halloran PJ, Fenton RG . 1998 Cancer Res. 58: 3855–3865

  • Hamel W, Magnelli L, Chiarugi VP, Israel MA . 1996 Cancer Res. 56: 2697–2702

  • Hu T, Miller CM, Ridder GM, Aardema MJ . 1999 Mutat. Res. 426: 51–62

  • Ioannou YA, Chen FW . 1996 Nucl. Acids Res. 24: 992–993

  • Izquierdo M, Martin V, de Felipe P, Izquierdo JM, Peres-Higueras A, Cortes ML, Paz JF, Isla A, Blazques MG . 1996 Gene Ther. 3: 491–495

  • Kaina B, Ziouta A, Ochs K, Coquerelle T . 1997 Mutat. Res. 381: 227–241

  • Kirsch DG, Deseff A, Chau BN, Lim D-S, de Souza-pinto NC, Hansford R, Kastan MB, Lazebnik YA, Hardwick JM . 1999 J. Biol. Chem. 274: 21155–21161

  • Klatzmann D, Phillipon J, Valery A, Bensimon G, Salzmann J-L . 1996 Hum. Gene Ther. 7: 109–126

  • Klaude M, Eriksson S, Nygren J, Ahnstrom G . 1996 Mutat. Res. 363: 89–96

  • Lee H, Larner JM, Mamlin JL . 1997 Gene 184: 177–183

  • Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X . 1997 Cell 91: 479–489

  • Lips J, Kaina B . 2001 Carcinogenesis 22: 579–585

  • Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H . 1996 Proc. Natl. Acad. Sci. USA 93: 1831–1835

  • Moolten FL . 1986 Cancer Res. 46: 5276–5281

  • Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedmann SL, Galle PR, Stremmel W, Oren M, Krammer PH . 1998 J. Exp. Med. 188: 2033–2045

  • Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C . 1991 J. Immunol. Meth. 139: 271–279

  • Obe G, Palitt F, Tanzarella C, Degrassi F, De Salvia R . 1985 Mutat. Res. 150: 359–368

  • Ochs K, Kaina B . 2000 Cancer Res. 60: 5815–5824

  • Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF . 1993 Hum. Gene Ther. 4: 39–69

  • Olive PL, Wlodek D, Banath JP . 1991 Cancer Res. 51: 4671–4676

  • Orren DK, Petersen LN, Bohr VA . 1995 Mol. Cell. Biol. 15: 3722–3730

  • Radford IR, Murphy TK . 1994 Int. J. Radiat. Biol. 65: 229–239

  • Rubsam LZ, Davidson BL, Shewach DS . 1998 Cancer Res. 58: 3873–3882

  • Seol DW, Billiar TR . 1999 J. Biol. Chem. 274: 2072–2076

  • Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ . 1999 J. Cell Biol. 144: 281–292

  • Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES . 1996 Proc. Natl. Acad. Sci. USA 93: 14486–14491

  • Srinivasula SM, Ahmad M, Guo Y, Zhan Y, Lazebnik Y, Fernandes-Alnemri T, Alnemri ES . 1999 Cancer Res. 59: 999–1002

  • Sun X-M, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM . 1999 J. Biol. Chem. 274: 5053–5060

  • Thust R, Tomicic M, Klöcking R, Voutilainen N, Wutzler P, Kaina B . 2000a Cancer Gene Ther. 7: 107–117

  • Thust R, Tomicic M, Klöcking R, Wutzler P, Kaina B . 2000b Mutagenesis 15: 177–184

  • Tomicic MT, Eschbach E, Kaina B . 1997 Mutat. Res. 383: 155–165

  • Tomicic MT, Christmann M, Kaina B . 2000 Biochem. Biophys. Res. Commun. 275: 899–903

  • Tomicic MT, Kaina B . 2001 Biochem. Biophys. Res. Commun. 281: 404–408

  • Vermes I, Haanen C, Steffens-Nakken H, Reutlingsberger C . 1995 J. Immunol. Meth. 184: 39–51

  • Wang X, Studzinski GP . 1997 Exp. Cell Res. 235: 210–217

  • Wei SJ, Chao Y, Hung YM, Lin WC, Yang DM, Shih YL, Chang LY, Whang-Peng J, Yang WK . 1998 Exp. Cell Res. 241: 66–75

  • Wei SJ, Chao Y, Shih YL, Yang DM, Hung YM, Yang WK . 1999 Gene Ther. 6: 420–431

  • Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K . 1999 Blood 93: 3053–3063

Download references

Acknowledgements

We are grateful to Dr Vincenz (Univesity of Michigan, USA) for the generous gift of the ICE–LAP6–Flag, ICE–LAP6–mt-Flag and AU1–Yama-mt constructs. We thank Dr Markus Christmann for helpful discussion and critical reading of the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft (grants KA 724/7-1 and 7-3 to B Kaina and TH 670/1-2 to R Thust) and the Stiftung Rheinland-Pfalz.

Author information

Authors and Affiliations

  1. Division of Applied Toxicology, Institute of Toxicology, Medical Faculty, University of Mainz, Obere Zahlbacher Str. 67, D-55131 Mainz, Germany

    Maja T Tomicic & Bernd Kaina

  2. Institute for Antiviral Chemotherapy, Medical Faculty, University of Jena, Winzerlaer Str. 10, D-07745 Jena, Germany

    Rudolf Thust

Authors
  1. Maja T Tomicic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rudolf Thust
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernd Kaina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernd Kaina.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tomicic, M., Thust, R. & Kaina, B. Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene 21, 2141–2153 (2002). https://doi.org/10.1038/sj.onc.1205280

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205280

Keywords

This article is cited by

Search

Advanced search

Quick links